173 related articles for article (PubMed ID: 32929653)
1. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line.
Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
Mol Biol Rep; 2019 Dec; 46(6):6361-6370. PubMed ID: 31583572
[TBL] [Abstract][Full Text] [Related]
3. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
[TBL] [Abstract][Full Text] [Related]
4. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by Z
Siavoshinia L; Jamalan M; Zeinali M; Pourshohod A; Koushki M; Moradipoodeh B; Mohammadzadeh G
Iran J Pathol; 2021; 16(2):109-118. PubMed ID: 33936221
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
[TBL] [Abstract][Full Text] [Related]
6. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
[TBL] [Abstract][Full Text] [Related]
7. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
10. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
Dong D; Xia G; Li Z; Li Z
Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
[TBL] [Abstract][Full Text] [Related]
11. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
12. Immunological Responses against HER2-targeted Idarubicin-ZHER2 Conjugate in BALB/c Mice.
Siavoshinia L; Jamalan M; Zeinali M; Mohammadzadeh G
Iran J Allergy Asthma Immunol; 2019 Oct; 18(5):501-510. PubMed ID: 32245294
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
14. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model.
Jiao H; Zhao X; Liu J; Ma T; Zhang Z; Zhang J; Wang J
Nucl Med Biol; 2019; 68-69():31-39. PubMed ID: 30578135
[TBL] [Abstract][Full Text] [Related]
16. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer.
Yamaguchi H; On J; Morita T; Suzuki T; Okada Y; Ono J; Evdokiou A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830099
[TBL] [Abstract][Full Text] [Related]
17. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
19. Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.
Sochaj-Gregorczyk AM; Ludzia P; Kozdrowska E; Jakimowicz P; Sokolowska-Wedzina A; Otlewski J
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771178
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
